b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31629013</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>19</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>19</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1879-3185</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>428</Volume>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>12</Month>\n                        <Day>01</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Toxicology</Title>\n                <ISOAbbreviation>Toxicology</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Telmisartan and captopril ameliorate pregabalin-induced heart failure in rats.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>152310</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0300-483X(19)30267-7</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tox.2019.152310</ELocationID>\n            <Abstract>\n                <AbstractText>Pregabalin (PRG) is highly effective in the treatment of epilepsy, neuropathic pain and anxiety disorders. Despite its potential benefits, PRG administration has been reported to induce or exacerbate heart failure (HF). It has been previously documented that overactivation of the renin angiotensin system (RAS) is involved in HF pathophysiological mechanism. The target of the current study was to examine the possible cardioprotective effect of telmisartan (Tel), an angiotensin II type 1 receptor (AT1R) blocker, compared with that of captopril (Cap), an angiotensin converting enzyme (ACE) inhibitor, in ameliorating PRG-induced HF in rats by assessing morphometric, echocardiographic and histopathological parameters. Furthermore, to investigate the role of RAS blockade by the two drugs in guarding against PRG-induced changes in cardiac angiotensin 1-7 (Ang 1-7) and angiotensin II (Ang II) levels, in addition to myocardial expression of ACE2, ACE, Mas receptor (MasR) and AT1R. Results showed that PRG administration induced morphometric, echocardiographic and histopathological deleterious alterations and significantly elevated cardiac Ang II, ACE and AT1R levels, while reduced Ang 1-7, ACE2 and MasR cardiac levels. Concurrent treatment with either Tel or Cap reversed PRG-induced morphometric, echocardiographic and histopathological abnormalities and revealed prominent protection against PRG-induced HF via downregulation of ACE/Ang II/AT1R and upregulation of ACE2/Ang 1-7/MasR axes. These are the first findings to demonstrate that the potential benefits of Tel and Cap are mediated by counteracting the altered balance between the RAS axes induced by PRG. Hence; Tel and Cap may attenuate PRG-induced HF partially through stimulation of ACE2/Ang 1-7/MasR pathway.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Awwad</LastName>\n                    <ForeName>Zeinab M</ForeName>\n                    <Initials>ZM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Therapeutics, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Alexandria, Egypt. Electronic address: Zeinab.awwad@pua.edu.eg.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>El-Ganainy</LastName>\n                    <ForeName>Samar O</ForeName>\n                    <Initials>SO</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Therapeutics, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Alexandria, Egypt.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>ElMallah</LastName>\n                    <ForeName>Ahmed I</ForeName>\n                    <Initials>AI</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Khattab</LastName>\n                    <ForeName>Mahmoud M</ForeName>\n                    <Initials>MM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>El-Khatib</LastName>\n                    <ForeName>Aiman S</ForeName>\n                    <Initials>AS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>16</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Ireland</Country>\n            <MedlineTA>Toxicology</MedlineTA>\n            <NlmUniqueID>0361055</NlmUniqueID>\n            <ISSNLinking>0300-483X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D047228">Angiotensin II Type 1 Receptor Blockers</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D044140">Receptor, Angiotensin, Type 1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C109794">pro-brain natriuretic peptide (1-76)</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="C049313">proto-oncogene proteins c-mas-1</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>114471-18-0</RegistryNumber>\n                <NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>55JG375S6M</RegistryNumber>\n                <NameOfSubstance UI="D000069583">Pregabalin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>9G64RSX1XD</RegistryNumber>\n                <NameOfSubstance UI="D002216">Captopril</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.7.11.11</RegistryNumber>\n                <NameOfSubstance UI="D017868">Cyclic AMP-Dependent Protein Kinases</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.4.15.1</RegistryNumber>\n                <NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.4.17.-</RegistryNumber>\n                <NameOfSubstance UI="C413524">angiotensin converting enzyme 2</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>U5SYW473RQ</RegistryNumber>\n                <NameOfSubstance UI="D000077333">Telmisartan</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D047228" MajorTopicYN="N">Angiotensin II Type 1 Receptor Blockers</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D002216" MajorTopicYN="N">Captopril</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017868" MajorTopicYN="N">Cyclic AMP-Dependent Protein Kinases</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName>\n                <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000069583" MajorTopicYN="N">Pregabalin</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D044140" MajorTopicYN="N">Receptor, Angiotensin, Type 1</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000077333" MajorTopicYN="N">Telmisartan</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Captopril</Keyword>\n            <Keyword MajorTopicYN="Y">Heart failure</Keyword>\n            <Keyword MajorTopicYN="Y">Pregabalin</Keyword>\n            <Keyword MajorTopicYN="Y">Telmisartan</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>14</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>09</Month>\n                <Day>19</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>15</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>5</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31629013</ArticleId>\n            <ArticleId IdType="pii">S0300-483X(19)30267-7</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.tox.2019.152310</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'